These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 23717451)

  • 1. Rates of switching antiretroviral drugs in a primary care service in South Africa before and after introduction of tenofovir.
    Njuguna C; Orrell C; Kaplan R; Bekker LG; Wood R; Lawn SD
    PLoS One; 2013; 8(5):e63596. PubMed ID: 23717451
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of tenofovir, zidovudine, or stavudine as part of first-line antiretroviral therapy in a resource-limited-setting: a cohort study.
    Velen K; Lewis JJ; Charalambous S; Grant AD; Churchyard GJ; Hoffmann CJ
    PLoS One; 2013; 8(5):e64459. PubMed ID: 23691224
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adverse drug reactions to antiretroviral therapy (ARVs): incidence, type and risk factors in Nigeria.
    Eluwa GI; Badru T; Agu KA; Akpoigbe KJ; Chabikuli O; Hamelmann C
    BMC Clin Pharmacol; 2012 Feb; 12():7. PubMed ID: 22369677
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tenofovir or zidovudine in three-drug combination therapy with one nucleoside reverse transcriptase inhibitor and one non-nucleoside reverse transcriptase inhibitor for initial treatment of HIV infection in antiretroviral-naïve individuals.
    Spaulding A; Rutherford GW; Siegfried N
    Cochrane Database Syst Rev; 2010 Oct; (10):CD008740. PubMed ID: 20927777
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High prevalence of the K65R mutation in HIV-1 subtype C infected patients failing tenofovir-based first-line regimens in South Africa.
    Skhosana L; Steegen K; Bronze M; Lukhwareni A; Letsoalo E; Papathanasopoulos MA; Carmona SC; Stevens WS
    PLoS One; 2015; 10(2):e0118145. PubMed ID: 25659108
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increases in regimen durability associated with the introduction of tenofovir at a large public-sector clinic in Johannesburg, South Africa.
    Brennan AT; Maskew M; Ive P; Shearer K; Long L; Sanne I; Fox MP
    J Int AIDS Soc; 2013 Nov; 16(1):18794. PubMed ID: 24256692
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost and cost-effectiveness of switching from d4T or AZT to a TDF-based first-line regimen in a resource-limited setting in rural Lesotho.
    Jouquet G; Bygrave H; Kranzer K; Ford N; Gadot L; Lee J; Hilderbrand K; Goemaere E; Vlahakis N; Trivino L; Makakole L; Cleary S
    J Acquir Immune Defic Syndr; 2011 Nov; 58(3):e68-74. PubMed ID: 21765366
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost and cost-effectiveness of switching from stavudine to tenofovir in first-line antiretroviral regimens in South Africa.
    Rosen S; Long L; Fox M; Sanne I
    J Acquir Immune Defic Syndr; 2008 Jul; 48(3):334-44. PubMed ID: 18545151
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early clinical and programmatic outcomes with tenofovir-based antiretroviral therapy in Zambia.
    Chi BH; Mwango A; Giganti M; Mulenga LB; Tambatamba-Chapula B; Reid SE; Bolton-Moore C; Chintu N; Mulenga PL; Stringer EM; Sheneberger R; Mwaba P; Stringer JS
    J Acquir Immune Defic Syndr; 2010 May; 54(1):63-70. PubMed ID: 20009765
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is zidovudine first-line therapy virologically comparable to tenofovir in resource-limited settings?
    Labhardt ND; Bader J; Lejone TI; Ringera I; Puga D; Glass TR; Klimkait T
    Trop Med Int Health; 2015 Jul; 20(7):914-8. PubMed ID: 25782332
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adherence, virological outcome, and drug resistance in Chinese HIV patients receiving first-line antiretroviral therapy from 2011 to 2015.
    Liu P; Liao L; Xu W; Yan J; Zuo Z; Leng X; Wang J; Kan W; You Y; Xing H; Ruan Y; Shao Y
    Medicine (Baltimore); 2018 Dec; 97(50):e13555. PubMed ID: 30558015
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tenofovir in second-line ART in Zambia and South Africa: collaborative analysis of cohort studies.
    Wandeler G; Keiser O; Mulenga L; Hoffmann CJ; Wood R; Chaweza T; Brennan A; Prozesky H; Garone D; Giddy J; Chimbetete C; Boulle A; Egger M;
    J Acquir Immune Defic Syndr; 2012 Sep; 61(1):41-8. PubMed ID: 22743595
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of antiretroviral regimens containing abacavir with tenofovir in treatment-experienced patients: predictors of virological response and drug resistance evolution in a multi-cohort study.
    Di Giambenedetto S; Torti C; Prosperi M; Manca N; Lapadula G; Paraninfo G; Ladisa N; Zazzi M; Trezzi M; Cicconi P; Corsi P; Nasta P; Cauda R; De Luca A; ; ;
    Infection; 2009 Oct; 37(5):438-44. PubMed ID: 19669091
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiviral efficacy and genotypic resistance patterns of combination therapy with stavudine/tenofovir in highly active antiretroviral therapy experienced patients.
    Antinori A; Trotta MP; Nasta P; Bini T; Bonora S; Castagna A; Zaccarelli M; Quirino T; Landonio S; Merli S; Tozzi V; Di Perri G; Andreoni M; Perno CF; Carosi G
    Antivir Ther; 2006; 11(2):233-43. PubMed ID: 16640104
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regimen durability in HIV-infected children and adolescents initiating first-line antiretroviral therapy in a large public sector HIV cohort in South Africa.
    Bonawitz R; Brennan AT; Long L; Heeren T; Maskew M; Sanne I; Fox MP
    Trop Med Int Health; 2018 Jun; 23(6):650-660. PubMed ID: 29656449
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HIV-1 drug resistance testing is essential for heavily-treated patients switching from first- to second-line regimens in resource-limited settings: evidence from routine clinical practice in Cameroon.
    Takou D; Fokam J; Teto G; Santoro MM; Ceccherini-Silberstein F; Nanfack AJ; Sosso SM; Dambaya B; Salpini R; Billong SC; Gori C; Fokunang CN; Cappelli G; Colizzi V; Perno CF; Ndjolo A
    BMC Infect Dis; 2019 Mar; 19(1):246. PubMed ID: 30871487
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized, open-label study of the safety and efficacy of switching stavudine or zidovudine to tenofovir disoproxil fumarate in HIV-1-infected children with virologic suppression.
    Saez-Llorens X; Castaño E; Rathore M; Church J; Deville J; Gaur A; Estripeaut D; White K; Arterburn S; Enejosa JV; Cheng AK; Chuck SL; Rhee MS
    Pediatr Infect Dis J; 2015 Apr; 34(4):376-82. PubMed ID: 25760565
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [To evaluate the changes in body composition in male human immunodeficiency virus-related lipodystrophy after different treatment regimens by dual-energy X-ray absorptiometry].
    Zhou X; Yu W; Li T; Guo F; Lin Q; Shao H; Tian J; Xu Y; Sun P
    Zhonghua Nei Ke Za Zhi; 2014 Aug; 53(8):622-5. PubMed ID: 25376824
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of switching from zidovudine to tenofovir disoproxil fumarate on bone mineral density and markers of bone metabolism in virologically suppressed HIV-1 infected patients; a substudy of the PREPARE study.
    Cotter AG; Vrouenraets SM; Brady JJ; Wit FW; Fux CA; Furrer H; Brinkman K; Sabin CA; Reiss P; Mallon PW;
    J Clin Endocrinol Metab; 2013 Apr; 98(4):1659-66. PubMed ID: 23436922
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Examination of noninferiority, safety, and tolerability of lopinavir/ritonavir and raltegravir compared with lopinavir/ritonavir and tenofovir/ emtricitabine in antiretroviral-naïve subjects: the progress study, 48-week results.
    Reynes J; Lawal A; Pulido F; Soto-Malave R; Gathe J; Tian M; Fredrick LM; Podsadecki TJ; Nilius AM
    HIV Clin Trials; 2011; 12(5):255-67. PubMed ID: 22180523
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.